Merck Sees Hyzaar As Counter To Bristol Antihypertensive Vanlev
Executive Summary
Merck's defense of its antihypertensive franchise following the launch of Bristol-Myers Squibb's Vanlev will include an emphasis on the efficacy of its angiotensin II/diuretic combination product Hyzaar.
You may also be interested in...
ICH Suggests Antihypertensive Drug Trials Add Focus On Systolic Measures
Clinical trials for new antihypertensive drugs need an increased focus on systolic blood pressure reduction, an International Conference on Harmonization draft guidance on antihypertensive drug development states.
ICH Suggests Antihypertensive Drug Trials Add Focus On Systolic Measures
Clinical trials for new antihypertensive drugs need an increased focus on systolic blood pressure reduction, an International Conference on Harmonization draft guidance on antihypertensive drug development states.
Merck Zocor U.S. Sales Headed Past $3 Bil.: Company Sees 20% Growth
U.S. sales of Zocor appear on track to top $3 bil. in 2000 based on projections of 20% growth for the full year.